Good luck getting a decent fair price when they know everything about you.

Will Warren even be alive in five years?

Can anyone remember an add they saw on a page this week? What about one they clicked on? Ask your friends this. Most won't be able to.

I trained my replacement workers (yes plural) as follows: manager asked for an outline of topics, gave them three pages. They wanted to record the training, okay I'll only do one session a day because I need prep time. Instead of them letting me go at the end of the month it took an extra three months to finish. We recorded a hundred plus hours of video. There's been two sets of turnover already. It's a year since I finished and according to an insider still there, not one feature checked into source control. We were doing 30 points of features every two weeks when I was there. I offered to implement the system at a major plant to save them 1.5 million a year (their numbers) at one of the plants still using paper. Nope, the Indian team will do it. That's an MBA in charge with deep ties to all these out sourcing companies. Makes me ill.

The guys that replaced me from India haven't committed a single worthwhile feature since I left eight months ago. Guess svn is racist, they should have used git.

I wish I had kept copies of the 100 hours of screen recordings. Truly Oscar winning stuff, had my co-workers in tears the crap I was going on about. The perils of not running unit tests and so on. Good luck finding anything useful in that 100 hours.

I said f-it and went north to go treeplanting. Wrote an article about it here: http://www.tree-planter.com/20...

I was asked to train my replacement from India about one year ago. I gave my manager a list of everything they needed to know. They wanted me to do sessions to train them. I said fine, I need prep time for each session and I'm only doing one a day. They screen recorded each session and it took about a hundred hours over three months. I buried them in minutia. If anyone wants to go through it or search it there's a hundred hours of tedious monotone instruction. It's been eight months since I left, no significant features committed to source control. We were doing major releases every month previously. They are thinking of bringing us back now but it is too late we've all moved on to better work. Company is losing millions a year by not having all of their refineries using this custom system that's been eight years in development. Tens of millions to re write from scratch. I've heard they are considering bringing us back but we have all moved on to better things now.

I first posted this 13 years ago. Sad how long it takes http://m.slashdot.org/story/40...

Here's a small sample of papers to read. You can get the fully linked versions from the company's website:
http://www.integratir.com/custommessage.asp?ticker =t.onc&message=fourth

Reovirus enhances radiation cytotoxicity in vitro and in vivo

A Phase I study of a wild-type reovirus (Reolysin) given intravenously to patients with advanced malignancies

Reovirus salvage of squamous cell cancer-contaminated wounds

Efficacy of oncolytic reovirus against liver metastasis from pancreatic cancer of immunocompetent models

Process Design and Scale-Up of New Vaccine Concepts for Biodefense

Process Development of a Scaleable Purification Protocol for the Production of Reolysin, an Oncolytic, Reovirus-Based Therapeutic

Biological purging of breast cancer cell lines using a replication-competent oncolytic virus in human stem cell autografts

Individualized quality of life, standardized quality of life, and distress in patients undergoing a phase I trial of the novel therapeutic Reolysin (reovirus)

A Novel Intravesical Therapy for Superficial Bladder Cancer in an Orthotopic Model: Oncolytic Reovirus Therapy

The oncolytic reovirus, Reolysin, augments the anticancer effects of cytotoxic agents in vitro against the ras-mutated human colon cancer cell line HCT 116

Reovirus Prolongs Survival and Reduces the Frequency of Spinal and Leptomeningeal Metastases from Medulloblastoma

Selective reovirus killing of bladder cancer in a co-culture spheroid model

Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation

Oncolytic Viral Therapy for Human Pancreatic Cancer Cells by Reovirus.

Systemic Reovirus Therapy of Metastatic Cancer in Immune-competent Mice

Reovirus therapy of lymphoid malignancies

AACR Annual Meeting Abstracts - The search word for the abstracts is "reovirus".

ASCO Annual Meeting Abstracts - The search word for the abstracts is "reovirus".

Reovirus as an oncolytic agent against experimental human malignant gliomas

A phase I clinical trial evaluating intralesional REOLYSIN (Reovirus) in histologically confirmed malignancies

Reovirus Induces Apoptosis in Breast and Prostate Cell Lines and Activates Nf-kB in the Nucleus: Implications for a Prognostic Factor in successful Reovirus Therapy

In Vitro and in Vivo Response of Malignant Non-Hodgkin's Lymphomas To Reovirus

Efficacy and Safety Evaluation of Human Reovirus Type 3 in a Immunocompetent Racine Glioma Model

Reovirus Prolongs Survival In Intracerebral Models Of Gliomas

Evaluation Of Reovirus Therapy For Spontaneously Occurring Canine Tumours

The Journal of Clinical Investigation - "Reovirus as a novel oncolytic agent"

Novel Viral Oncolytic Therapy Of Superficial Bladder Cancer In An Animal Model: A Comparative Study To BCG.

Reovirus Therapy of Metastatic Cancer Models in Immune-Competent Mice